Lactate-producing intratumoral bacteria drive resistance to radiation therapy

Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy, suggesting that lactic acid-producing bacteria present in various cancers may serve as novel therapeutic targets.

Pfizer invests $98M in Australian manufacturing to help develop new antimicrobial treatments

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 8, 2024

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Ivonescimab — a novel first-in-class PD-1/VEGF bispecific antibody — led to clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) as first-line therapy

September 10, 2024

Unlocking the secrets of our body’s first line of defense against strep throat and more

Researchers have mapped the complex structures of secretory immunoglobulin A (sIgA) in interaction with human CD89 and Streptococcus pyogenes M4, offering new insights into how

September 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.